TIP60 is required for tumorigenesis in non‐small cell lung cancer
Histone modifications play crucial roles in transcriptional activation, and aberrant epigenetic changes are associated with oncogenesis. Lysine (K) acetyltransferases 5 (TIP60, also known as KAT5) is reportedly implicated in cancer development and maintenance, although its function in lung cancer re...
Saved in:
Published in | Cancer science Vol. 114; no. 6; pp. 2400 - 2413 |
---|---|
Main Authors | , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
John Wiley & Sons, Inc
01.06.2023
John Wiley and Sons Inc |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Histone modifications play crucial roles in transcriptional activation, and aberrant epigenetic changes are associated with oncogenesis. Lysine (K) acetyltransferases 5 (TIP60, also known as KAT5) is reportedly implicated in cancer development and maintenance, although its function in lung cancer remains controversial. Here we demonstrate that TIP60 knockdown in non‐small cell lung cancer cell lines decreased tumor cell growth, migration, and invasion. Furthermore, analysis of a mouse lung cancer model with lung‐specific conditional Tip60 knockout revealed suppressed tumor formation relative to controls, but no apparent effects on normal lung homeostasis. RNA‐seq and ChIP‐seq analyses of inducible TIP60 knockdown H1975 cells relative to controls revealed transglutaminase enzyme (TGM5) as downstream of TIP60. Investigation of a connectivity map database identified several candidate compounds that decrease TIP60 mRNA, one that suppressed tumor growth in cell culture and in vivo. In addition, TH1834, a TIP60 acetyltransferase inhibitor, showed comparable antitumor effects in cell culture and in vivo. Taken together, suppression of TIP60 activity shows tumor‐specific efficacy against lung cancer, with no overt effect on normal tissues. Our work suggests that targeting TIP60 could be a promising approach to treating lung cancer.
Genetic and pharmacological inhibition of TIP60 attenuates tumorigenesis in non‐small cell lung cancer, implicating that targeting TIP60 could be a novel approach for lung cancer treatment. |
---|---|
AbstractList | Histone modifications play crucial roles in transcriptional activation, and aberrant epigenetic changes are associated with oncogenesis. Lysine (K) acetyltransferases 5 (TIP60, also known as KAT5) is reportedly implicated in cancer development and maintenance, although its function in lung cancer remains controversial. Here we demonstrate that TIP60 knockdown in non-small cell lung cancer cell lines decreased tumor cell growth, migration, and invasion. Furthermore, analysis of a mouse lung cancer model with lung-specific conditional Tip60 knockout revealed suppressed tumor formation relative to controls, but no apparent effects on normal lung homeostasis. RNA-seq and ChIP-seq analyses of inducible TIP60 knockdown H1975 cells relative to controls revealed transglutaminase enzyme (TGM5) as downstream of TIP60. Investigation of a connectivity map database identified several candidate compounds that decrease TIP60 mRNA, one that suppressed tumor growth in cell culture and in vivo. In addition, TH1834, a TIP60 acetyltransferase inhibitor, showed comparable antitumor effects in cell culture and in vivo. Taken together, suppression of TIP60 activity shows tumor-specific efficacy against lung cancer, with no overt effect on normal tissues. Our work suggests that targeting TIP60 could be a promising approach to treating lung cancer.Histone modifications play crucial roles in transcriptional activation, and aberrant epigenetic changes are associated with oncogenesis. Lysine (K) acetyltransferases 5 (TIP60, also known as KAT5) is reportedly implicated in cancer development and maintenance, although its function in lung cancer remains controversial. Here we demonstrate that TIP60 knockdown in non-small cell lung cancer cell lines decreased tumor cell growth, migration, and invasion. Furthermore, analysis of a mouse lung cancer model with lung-specific conditional Tip60 knockout revealed suppressed tumor formation relative to controls, but no apparent effects on normal lung homeostasis. RNA-seq and ChIP-seq analyses of inducible TIP60 knockdown H1975 cells relative to controls revealed transglutaminase enzyme (TGM5) as downstream of TIP60. Investigation of a connectivity map database identified several candidate compounds that decrease TIP60 mRNA, one that suppressed tumor growth in cell culture and in vivo. In addition, TH1834, a TIP60 acetyltransferase inhibitor, showed comparable antitumor effects in cell culture and in vivo. Taken together, suppression of TIP60 activity shows tumor-specific efficacy against lung cancer, with no overt effect on normal tissues. Our work suggests that targeting TIP60 could be a promising approach to treating lung cancer. Abstract Histone modifications play crucial roles in transcriptional activation, and aberrant epigenetic changes are associated with oncogenesis. Lysine (K) acetyltransferases 5 (TIP60, also known as KAT5) is reportedly implicated in cancer development and maintenance, although its function in lung cancer remains controversial. Here we demonstrate that TIP60 knockdown in non‐small cell lung cancer cell lines decreased tumor cell growth, migration, and invasion. Furthermore, analysis of a mouse lung cancer model with lung‐specific conditional Tip60 knockout revealed suppressed tumor formation relative to controls, but no apparent effects on normal lung homeostasis. RNA‐seq and ChIP‐seq analyses of inducible TIP60 knockdown H1975 cells relative to controls revealed transglutaminase enzyme (TGM5) as downstream of TIP60. Investigation of a connectivity map database identified several candidate compounds that decrease TIP60 mRNA, one that suppressed tumor growth in cell culture and in vivo . In addition, TH1834, a TIP60 acetyltransferase inhibitor, showed comparable antitumor effects in cell culture and in vivo . Taken together, suppression of TIP60 activity shows tumor‐specific efficacy against lung cancer, with no overt effect on normal tissues. Our work suggests that targeting TIP60 could be a promising approach to treating lung cancer. Histone modifications play crucial roles in transcriptional activation, and aberrant epigenetic changes are associated with oncogenesis. Lysine (K) acetyltransferases 5 (TIP60, also known as KAT5) is reportedly implicated in cancer development and maintenance, although its function in lung cancer remains controversial. Here we demonstrate that TIP60 knockdown in non‐small cell lung cancer cell lines decreased tumor cell growth, migration, and invasion. Furthermore, analysis of a mouse lung cancer model with lung‐specific conditional Tip60 knockout revealed suppressed tumor formation relative to controls, but no apparent effects on normal lung homeostasis. RNA‐seq and ChIP‐seq analyses of inducible TIP60 knockdown H1975 cells relative to controls revealed transglutaminase enzyme (TGM5) as downstream of TIP60. Investigation of a connectivity map database identified several candidate compounds that decrease TIP60 mRNA, one that suppressed tumor growth in cell culture and in vivo. In addition, TH1834, a TIP60 acetyltransferase inhibitor, showed comparable antitumor effects in cell culture and in vivo. Taken together, suppression of TIP60 activity shows tumor‐specific efficacy against lung cancer, with no overt effect on normal tissues. Our work suggests that targeting TIP60 could be a promising approach to treating lung cancer. Genetic and pharmacological inhibition of TIP60 attenuates tumorigenesis in non‐small cell lung cancer, implicating that targeting TIP60 could be a novel approach for lung cancer treatment. Histone modifications play crucial roles in transcriptional activation, and aberrant epigenetic changes are associated with oncogenesis. Lysine (K) acetyltransferases 5 (TIP60, also known as KAT5) is reportedly implicated in cancer development and maintenance, although its function in lung cancer remains controversial. Here we demonstrate that TIP60 knockdown in non-small cell lung cancer cell lines decreased tumor cell growth, migration, and invasion. Furthermore, analysis of a mouse lung cancer model with lung-specific conditional Tip60 knockout revealed suppressed tumor formation relative to controls, but no apparent effects on normal lung homeostasis. RNA-seq and ChIP-seq analyses of inducible TIP60 knockdown H1975 cells relative to controls revealed transglutaminase enzyme (TGM5) as downstream of TIP60. Investigation of a connectivity map database identified several candidate compounds that decrease TIP60 mRNA, one that suppressed tumor growth in cell culture and in vivo. In addition, TH1834, a TIP60 acetyltransferase inhibitor, showed comparable antitumor effects in cell culture and in vivo. Taken together, suppression of TIP60 activity shows tumor-specific efficacy against lung cancer, with no overt effect on normal tissues. Our work suggests that targeting TIP60 could be a promising approach to treating lung cancer. Histone modifications play crucial roles in transcriptional activation, and aberrant epigenetic changes are associated with oncogenesis. Lysine (K) acetyltransferases 5 (TIP60, also known as KAT5) is reportedly implicated in cancer development and maintenance, although its function in lung cancer remains controversial. Here we demonstrate that TIP60 knockdown in non‐small cell lung cancer cell lines decreased tumor cell growth, migration, and invasion. Furthermore, analysis of a mouse lung cancer model with lung‐specific conditional Tip60 knockout revealed suppressed tumor formation relative to controls, but no apparent effects on normal lung homeostasis. RNA‐seq and ChIP‐seq analyses of inducible TIP60 knockdown H1975 cells relative to controls revealed transglutaminase enzyme (TGM5) as downstream of TIP60. Investigation of a connectivity map database identified several candidate compounds that decrease TIP60 mRNA, one that suppressed tumor growth in cell culture and in vivo . In addition, TH1834, a TIP60 acetyltransferase inhibitor, showed comparable antitumor effects in cell culture and in vivo . Taken together, suppression of TIP60 activity shows tumor‐specific efficacy against lung cancer, with no overt effect on normal tissues. Our work suggests that targeting TIP60 could be a promising approach to treating lung cancer. Genetic and pharmacological inhibition of TIP60 attenuates tumorigenesis in non‐small cell lung cancer, implicating that targeting TIP60 could be a novel approach for lung cancer treatment. |
Author | Akanuma, Naoki Jiang, Feng Heo, Eunyoung Kobayashi, Ikei S. Watanabe, Hideo Shibahara, Daisuke Bararia, Deepak Costa, Daniel B. Ando, Mariko Tenen, Daniel G. Pan, Gilbert Prin, P. Nicholas Wong, Kwok‐Kin Fujii, Masanori Kobayashi, Susumu S. |
AuthorAffiliation | 5 Perlmutter Cancer Center NYU Langone Medical Center New York New York USA 1 Department of Medicine, Beth Israel Deaconess Medical Center Harvard Medical School Boston Massachusetts USA 4 Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, Department of Genetics and Genomic Sciences Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai New York New York USA 8 Division of Translational Genomics, Exploratory Oncology Research and Clinical Trial Center National Cancer Center Kashiwa Japan 3 Department of Internal Medicine SMG‐SNU Boramae Medical Center Seoul South Korea 2 Department of Pathology University of California San Francisco San Francisco California USA 7 Cancer Science Institute of Singapore National University of Singapore Singapore Singapore 6 Harvard Stem Cell Institute, Harvard Medical School Boston Massachusetts USA |
AuthorAffiliation_xml | – name: 2 Department of Pathology University of California San Francisco San Francisco California USA – name: 5 Perlmutter Cancer Center NYU Langone Medical Center New York New York USA – name: 6 Harvard Stem Cell Institute, Harvard Medical School Boston Massachusetts USA – name: 3 Department of Internal Medicine SMG‐SNU Boramae Medical Center Seoul South Korea – name: 7 Cancer Science Institute of Singapore National University of Singapore Singapore Singapore – name: 4 Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, Department of Genetics and Genomic Sciences Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai New York New York USA – name: 1 Department of Medicine, Beth Israel Deaconess Medical Center Harvard Medical School Boston Massachusetts USA – name: 8 Division of Translational Genomics, Exploratory Oncology Research and Clinical Trial Center National Cancer Center Kashiwa Japan |
Author_xml | – sequence: 1 givenname: Daisuke surname: Shibahara fullname: Shibahara, Daisuke organization: Harvard Medical School – sequence: 2 givenname: Naoki surname: Akanuma fullname: Akanuma, Naoki organization: University of California San Francisco – sequence: 3 givenname: Ikei S. surname: Kobayashi fullname: Kobayashi, Ikei S. organization: Harvard Medical School – sequence: 4 givenname: Eunyoung surname: Heo fullname: Heo, Eunyoung organization: SMG‐SNU Boramae Medical Center – sequence: 5 givenname: Mariko surname: Ando fullname: Ando, Mariko organization: Harvard Medical School – sequence: 6 givenname: Masanori surname: Fujii fullname: Fujii, Masanori organization: Harvard Medical School – sequence: 7 givenname: Feng surname: Jiang fullname: Jiang, Feng organization: Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai – sequence: 8 givenname: P. Nicholas surname: Prin fullname: Prin, P. Nicholas organization: Harvard Medical School – sequence: 9 givenname: Gilbert surname: Pan fullname: Pan, Gilbert organization: Harvard Medical School – sequence: 10 givenname: Kwok‐Kin surname: Wong fullname: Wong, Kwok‐Kin organization: NYU Langone Medical Center – sequence: 11 givenname: Daniel B. surname: Costa fullname: Costa, Daniel B. organization: Harvard Medical School – sequence: 12 givenname: Deepak surname: Bararia fullname: Bararia, Deepak organization: Harvard Stem Cell Institute, Harvard Medical School – sequence: 13 givenname: Daniel G. surname: Tenen fullname: Tenen, Daniel G. organization: National University of Singapore – sequence: 14 givenname: Hideo surname: Watanabe fullname: Watanabe, Hideo organization: Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai – sequence: 15 givenname: Susumu S. orcidid: 0000-0003-2262-4001 surname: Kobayashi fullname: Kobayashi, Susumu S. email: skobayas@bidmc.harvard.edu organization: National Cancer Center |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/36916958$$D View this record in MEDLINE/PubMed |
BookMark | eNp1kctKAzEUhoMo1tvCF5ABN7oYm0xuMyuR4qVQULCuQybN1JSZpCYdxZ2P4DP6JMZOLSqYRRI4H1_Oyb8LNq2zGoBDBM9QXH0lwxmiPKcbYAdhUqQcQra5vPO0gDjrgd0QZhBiRgqyDXqYFYgVNN8Bg_HwjsHEhMTrp9Z4PUkq55NF2zhvptrqEEvGJvHFj7f30Mi6TpSOW93aaaKkVdrvg61K1kEfrM498HB1OR7cpKPb6-HgYpQqwnKaMj2RJeVVUcCqgohAzjKSkxIjIssScqU4hTKniJQlxZRqiqUkZYYwZhOqIN4D55133paNnihtF17WYu5NI_2rcNKI3xVrHsXUPQsEM8wYLqLhZGXw7qnVYSEaE77GkVa7NoiM5yxHGUI8osd_0JlrvY3ziSzP4m8zwnGkTjtKeReC19W6GwTFVzYiZiOW2UT26Gf7a_I7jAj0O-DF1Pr1f5MYXNx3yk_0w5ng |
CitedBy_id | crossref_primary_10_1002_mog2_59 crossref_primary_10_1016_j_biopha_2023_115741 crossref_primary_10_1136_bmjonc_2023_000154 |
Cites_doi | 10.1016/j.yexcr.2017.11.028 10.1074/jbc.M102553200 10.1158/0008-5472.CAN-17-0388 10.1016/j.ccell.2019.10.002 10.1038/nature03452 10.1074/jbc.M111.278465 10.1038/s41576-018-0072-4 10.1016/j.molcel.2006.11.021 10.1016/S0092-8674(00)00051-9 10.1038/s41388-021-01847-w 10.1016/j.tcb.2006.07.007 10.1371/journal.pone.0164855 10.1002/dvdy.22110 10.1038/nrmicro2239 10.1007/s00280-018-3533-8 10.1038/s41388-021-02058-z 10.1002/jcp.27875 10.1242/dmm.049786 10.1186/s12885-021-08158-z 10.7150/jca.19677 10.3322/caac.21654 10.1016/j.biocel.2006.03.003 10.1038/nature06055 10.1111/1759-7714.13570 10.1038/cdd.2015.173 10.1016/j.molcel.2011.03.033 10.1038/nrm1014 10.1038/emboj.2010.333 10.1016/j.semcancer.2017.02.009 10.1093/bfgp/ell028 10.1016/j.ccr.2007.06.005 10.1182/blood.2019001279 10.1038/ng1361 10.1007/s10549-017-4261-1 10.1038/onc.2008.499 10.1074/jbc.M113.458737 10.1021/acschembio.8b00705 10.1158/0008-5472.CAN-10-2852 10.1111/exd.13449 10.1038/onc.2012.442 10.1007/s00726-004-0093-5 10.1074/jbc.M010157200 10.1038/s41573-021-00371-6 10.1042/BST20160081 10.1038/srep05372 10.1158/0008-5472.CAN-20-2379 |
ContentType | Journal Article |
Copyright | 2023 The Authors. published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. 2023 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. 2023. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
Copyright_xml | – notice: 2023 The Authors. published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. – notice: 2023 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. – notice: 2023. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
DBID | 24P WIN CGR CUY CVF ECM EIF NPM AAYXX CITATION 8FE 8FH ABUWG AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO GNUQQ HCIFZ LK8 M7P PIMPY PQEST PQQKQ PQUKI PRINS 7X8 5PM |
DOI | 10.1111/cas.15785 |
DatabaseName | Wiley-Blackwell Open Access Collection Wiley-Blackwell Backfiles (Open access) Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef ProQuest SciTech Collection ProQuest Natural Science Collection ProQuest Central (Alumni) ProQuest Central ProQuest Central Essentials Biological Science Collection ProQuest Databases Natural Science Collection ProQuest One Community College ProQuest Central ProQuest Central Student SciTech Premium Collection Biological Sciences Biological Science Database Publicly Available Content Database ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Publicly Available Content Database ProQuest Central Student ProQuest Biological Science Collection ProQuest Central Essentials ProQuest One Academic Eastern Edition ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest Natural Science Collection Biological Science Database ProQuest SciTech Collection ProQuest Central China ProQuest Central ProQuest One Academic UKI Edition Natural Science Collection ProQuest Central Korea Biological Science Collection ProQuest One Academic MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic CrossRef MEDLINE Publicly Available Content Database |
Database_xml | – sequence: 1 dbid: 24P name: Wiley_OA刊 url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html sourceTypes: Publisher – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: BENPR name: AUTh Library subscriptions: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
DocumentTitleAlternate | Shibahara et al |
EISSN | 1349-7006 |
EndPage | 2413 |
ExternalDocumentID | 10_1111_cas_15785 36916958 CAS15785 |
Genre | researchArticle Journal Article |
GrantInformation_xml | – fundername: National Cancer Institute funderid: CA197697; CA218707; CA240257 – fundername: NCI NIH HHS grantid: CA240257 – fundername: NCI NIH HHS grantid: R37 CA218707 – fundername: NCI NIH HHS grantid: R01 CA240257 – fundername: NIEHS NIH HHS grantid: P30 ES000002 – fundername: NCI NIH HHS grantid: CA197697 – fundername: NCI NIH HHS grantid: CA218707 – fundername: ; grantid: CA197697; CA218707; CA240257 |
GroupedDBID | --- .3N .55 .GA .Y3 05W 0R~ 10A 1OC 24P 29B 2WC 31~ 36B 3O- 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52W 52X 53G 5GY 5HH 5LA 5VS 66C 7.U 702 7PT 8-0 8-1 8-3 8-4 8-5 8FE 8FH 8UM 930 A01 A03 AAHHS AAZKR ABCQN ABEML ACCFJ ACSCC ACXQS ADBBV ADKYN ADZMN ADZOD AEEZP AENEX AEQDE AFBPY AFEBI AFFNX AFKRA AFPKN AFZJQ AIWBW AJBDE ALMA_UNASSIGNED_HOLDINGS ALUQN AOIJS AVUZU BAWUL BBNVY BCNDV BENPR BFHJK BHPHI BY8 CAG CCPQU COF CS3 D-6 D-7 D-E D-F DIK DR2 DU5 E3Z EBS EJD EMB EMOBN EX3 F00 F01 F04 F5P FIJ GODZA GROUPED_DOAJ HCIFZ HF~ HOLLA HYE HZI HZ~ IAO IHR IPNFZ IX1 J0M K.9 K48 KQ8 LC2 LC3 LH4 LK8 LP6 LP7 LW6 M7P MK4 N04 N05 N9A O9- OIG OK1 OVD P2P P2X P2Z P4B P4D PIMPY PROAC Q11 ROL RPM RX1 SJN SUPJJ SV3 TEORI UB1 W8V WIN WOW WQJ WRC WXI X7M XG1 ZXP ~IA ~WT CGR CUY CVF ECM EIF ITC NPM AAYXX CITATION ABUWG AZQEC DWQXO GNUQQ PQEST PQQKQ PQUKI PRINS 7X8 5PM |
ID | FETCH-LOGICAL-c4685-6edab57f990ff0140762484b314abb07cc750a8514bb5355e53aa4b21336d5c03 |
IEDL.DBID | RPM |
ISSN | 1347-9032 1349-7006 |
IngestDate | Tue Sep 17 21:30:00 EDT 2024 Wed Jul 24 13:46:53 EDT 2024 Thu Oct 10 18:26:26 EDT 2024 Thu Sep 26 15:42:03 EDT 2024 Fri Oct 18 09:10:33 EDT 2024 Sat Aug 24 00:53:51 EDT 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 6 |
Keywords | artemisinin lung cancer KAT5 TGM5 TIP60 |
Language | English |
License | Attribution-NonCommercial-NoDerivs 2023 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c4685-6edab57f990ff0140762484b314abb07cc750a8514bb5355e53aa4b21336d5c03 |
Notes | Daisuke Shibahara and Naoki Akanuma contributed equally to this work. ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ORCID | 0000-0003-2262-4001 |
OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10236639/ |
PMID | 36916958 |
PQID | 2821576473 |
PQPubID | 4378882 |
PageCount | 14 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_10236639 proquest_miscellaneous_2786812117 proquest_journals_2821576473 crossref_primary_10_1111_cas_15785 pubmed_primary_36916958 wiley_primary_10_1111_cas_15785_CAS15785 |
PublicationCentury | 2000 |
PublicationDate | June 2023 |
PublicationDateYYYYMMDD | 2023-06-01 |
PublicationDate_xml | – month: 06 year: 2023 text: June 2023 |
PublicationDecade | 2020 |
PublicationPlace | England |
PublicationPlace_xml | – name: England – name: Tokyo – name: Hoboken |
PublicationTitle | Cancer science |
PublicationTitleAlternate | Cancer Sci |
PublicationYear | 2023 |
Publisher | John Wiley & Sons, Inc John Wiley and Sons Inc |
Publisher_xml | – name: John Wiley & Sons, Inc – name: John Wiley and Sons Inc |
References | 2018; 362 2017; 8 2007; 448 2021; 21 2015; 5 2012; 287 2023; 16 2006; 38 2006; 16 2005; 434 2004; 26 2020; 80 2017; 46 2019; 36 2013; 288 2019; 17 2018; 81 2011; 30 2006; 5 2017; 171 2020; 11 2022; 21 2021; 71 2007; 12 2018; 27 2009; 28 2016; 11 2009; 238 2001; 276 2014; 4 2000; 102 2019; 20 2006; 24 2013; 32 2017; 77 2004; 36 2011; 71 2011; 42 2003; 4 2019; 234 2009; 7 2017; 164 2020; 136 2021; 40 2016; 23 2016; 44 2018; 13 e_1_2_11_32_1 e_1_2_11_30_1 e_1_2_11_13_1 e_1_2_11_34_1 e_1_2_11_11_1 e_1_2_11_29_1 e_1_2_11_6_1 e_1_2_11_27_1 e_1_2_11_4_1 e_1_2_11_48_1 e_1_2_11_2_1 e_1_2_11_20_1 e_1_2_11_45_1 e_1_2_11_47_1 e_1_2_11_24_1 e_1_2_11_41_1 e_1_2_11_8_1 e_1_2_11_22_1 e_1_2_11_43_1 e_1_2_11_17_1 Subramanian A (e_1_2_11_21_1) 2017; 171 e_1_2_11_15_1 e_1_2_11_38_1 e_1_2_11_19_1 e_1_2_11_50_1 e_1_2_11_10_1 e_1_2_11_31_1 e_1_2_11_14_1 e_1_2_11_35_1 e_1_2_11_12_1 e_1_2_11_33_1 e_1_2_11_7_1 e_1_2_11_5_1 e_1_2_11_26_1 e_1_2_11_3_1 e_1_2_11_49_1 e_1_2_11_44_1 e_1_2_11_46_1 e_1_2_11_25_1 e_1_2_11_40_1 Liang Z (e_1_2_11_28_1) 2019; 17 e_1_2_11_9_1 e_1_2_11_23_1 e_1_2_11_42_1 e_1_2_11_18_1 e_1_2_11_16_1 Huang L (e_1_2_11_36_1) 2015; 5 e_1_2_11_37_1 e_1_2_11_39_1 |
References_xml | – volume: 136 start-page: 1735 year: 2020 end-page: 1747 article-title: Lysine acetyltransferase Tip60 is required for hematopoietic stem cell maintenance publication-title: Blood – volume: 36 start-page: 498 issue: 5 year: 2019 end-page: 511 article-title: A potent and selective small‐molecule degrader of STAT3 achieves complete tumor regression publication-title: Cancer Cell – volume: 362 start-page: 279 year: 2018 end-page: 286 article-title: Acetylation of TIP60 at K104 is essential for metabolic stress‐induced apoptosis in cells of hepatocellular cancer publication-title: Exp Cell Res – volume: 7 start-page: 864 year: 2009 end-page: 874 article-title: Artemisinin‐based combination therapies: a vital tool in efforts to eliminate malaria publication-title: Nat Rev Microbiol – volume: 171 issue: 1437–1452 year: 2017 article-title: A next generation connectivity map: L1000 platform and the first 1,000,000 profiles publication-title: Cell – volume: 4 start-page: 140 year: 2003 end-page: 156 article-title: Transglutaminases: crosslinking enzymes with pleiotropic functions publication-title: Nat Rev Mol Cell Biol – volume: 77 start-page: 4973 year: 2017 end-page: 4984 article-title: Transglutaminase 2 inhibition reverses mesenchymal Transdifferentiation of glioma stem cells by regulating C/EBPbeta signaling publication-title: Cancer Res – volume: 276 start-page: 35014 year: 2001 end-page: 35023 article-title: Transglutaminase 5 cross‐links loricrin, involucrin, and small proline‐rich proteins in vitro publication-title: J Biol Chem – volume: 5 start-page: 209 year: 2006 end-page: 221 article-title: Histone acetylation in gene regulation publication-title: Brief Funct Genomic Proteomic – volume: 28 start-page: 1506 year: 2009 end-page: 1517 article-title: The p400/Tip60 ratio is critical for colorectal cancer cell proliferation through DNA damage response pathways publication-title: Oncogene – volume: 46 start-page: 65 year: 2017 end-page: 83 article-title: From ancient herb to modern drug: Artemisia annua and artemisinin for cancer therapy publication-title: Semin Cancer Biol – volume: 17 start-page: 3195 year: 2019 end-page: 3202 article-title: Tip60‐siRNA regulates ABCE1 acetylation to suppress lung cancer growth via activation of the apoptotic signaling pathway publication-title: Exp Ther Med – volume: 24 start-page: 827 year: 2006 end-page: 839 article-title: Tip60‐dependent acetylation of p53 modulates the decision between cell‐cycle arrest and apoptosis publication-title: Mol Cell – volume: 23 start-page: 1198 year: 2016 end-page: 1208 article-title: The acetyltransferase Tip60 contributes to mammary tumorigenesis by modulating DNA repair publication-title: Cell Death Differ – volume: 21 start-page: 181 year: 2022 end-page: 200 article-title: PROTAC targeted protein degraders: the past is prologue publication-title: Nat Rev Drug Discov – volume: 11 start-page: 2316 year: 2020 end-page: 2324 article-title: Combination treatment with artemisinin and oxaliplatin inhibits tumorigenesis in esophageal cancer EC109 cell through Wnt/beta‐catenin signaling pathway publication-title: Thorac Cancer – volume: 36 start-page: 624 year: 2004 end-page: 630 article-title: Acute myeloid leukemia induced by graded reduction of a lineage‐specific transcription factor, PU.1 publication-title: Nat Genet – volume: 26 start-page: 425 year: 2004 end-page: 430 article-title: Transglutaminase 5 is acetylated at the N‐terminal end publication-title: Amino Acids – volume: 5 start-page: 2756 year: 2015 end-page: 2776 article-title: Transglutaminase 2 in cancer publication-title: Am J Cancer Res – volume: 81 start-page: 587 year: 2018 end-page: 596 article-title: A phase I study of intravenous artesunate in patients with advanced solid tumor malignancies publication-title: Cancer Chemother Pharmacol – volume: 102 start-page: 463 year: 2000 end-page: 473 article-title: Involvement of the TIP60 histone acetylase complex in DNA repair and apoptosis publication-title: Cell – volume: 11 year: 2016 article-title: Depletion of Tip60 from In vivo Cardiomyocytes increases myocyte density, followed by cardiac dysfunction, myocyte fallout and lethality publication-title: PLoS One – volume: 234 start-page: 12663 year: 2019 end-page: 12675 article-title: Artemisinin inhibits breast cancer‐induced osteolysis by inhibiting osteoclast formation and breast cancer cell proliferation publication-title: J Cell Physiol – volume: 434 start-page: 921 year: 2005 end-page: 926 article-title: Transcriptional regulation of a metastasis suppressor gene by Tip60 and beta‐catenin complexes publication-title: Nature – volume: 80 start-page: 5543 year: 2020 end-page: 5553 article-title: Transcriptional activation of MYC‐induced genes by GCN5 promotes B‐cell lymphomagenesis publication-title: Cancer Res – volume: 16 start-page: 433 year: 2006 end-page: 442 article-title: Tip60 in DNA damage response and growth control: many tricks in one HAT publication-title: Trends Cell Biol – volume: 30 start-page: 510 year: 2011 end-page: 523 article-title: Acetylation and phosphorylation of SRSF2 control cell fate decision in response to cisplatin publication-title: EMBO J – volume: 288 start-page: 14510 year: 2013 end-page: 14521 article-title: Lysine acetyltransferase GCN5 potentiates the growth of non‐small cell lung cancer via promotion of E2F1, cyclin D1, and cyclin E1 expression publication-title: J Biol Chem – volume: 238 start-page: 2912 year: 2009 end-page: 2921 article-title: Homozygous disruption of the Tip60 gene causes early embryonic lethality publication-title: Dev Dyn – volume: 20 start-page: 7 year: 2019 end-page: 23 article-title: The many lives of KATs ‐ detectors, integrators and modulators of the cellular environment publication-title: Nat Rev Genet – volume: 12 start-page: 81 year: 2007 end-page: 93 article-title: Bronchial and peripheral murine lung carcinomas induced by T790M‐L858R mutant EGFR respond to HKI‐272 and rapamycin combination therapy publication-title: Cancer Cell – volume: 16 year: 2023 article-title: Pharmacological inhibition of the acetyltransferase Tip60 mitigates myocardial infarction injury publication-title: Dis Model Mech – volume: 44 start-page: 979 year: 2016 end-page: 986 article-title: Targeting cancer using KAT inhibitors to mimic lethal knockouts publication-title: Biochem Soc Trans – volume: 71 start-page: 7 year: 2021 end-page: 33 article-title: Cancer statistics, 2021 publication-title: CA Cancer J Clin – volume: 38 start-page: 1496 year: 2006 end-page: 1509 article-title: Cellular functions of TIP60 publication-title: Int J Biochem Cell Biol – volume: 40 start-page: 4352 year: 2021 end-page: 4367 article-title: Transglutaminase 2 promotes tumorigenicity of colon cancer cells by inactivation of the tumor suppressor p53 publication-title: Oncogene – volume: 27 start-page: 807 year: 2018 end-page: 814 article-title: Transglutaminases in autoimmune and inherited skin diseases: the phenomena of epitope spreading and functional compensation publication-title: Exp Dermatol – volume: 40 start-page: 6707 year: 2021 end-page: 6719 article-title: O‐GlcNAc modified‐TIP60/KAT5 is required for PCK1 deficiency‐induced HCC metastasis publication-title: Oncogene – volume: 21 start-page: 396 year: 2021 article-title: Kaempferol induces ROS‐dependent apoptosis in pancreatic cancer cells via TGM2‐mediated Akt/mTOR signaling publication-title: BMC Cancer – volume: 32 start-page: 4243 year: 2013 end-page: 4251 article-title: H2A.Z‐dependent crosstalk between enhancer and promoter regulates cyclin D1 expression publication-title: Oncogene – volume: 8 start-page: 2277 year: 2017 end-page: 2281 article-title: Tat‐interactive protein‐60KDA (TIP60) regulates the tumorigenesis of lung cancer In vitro publication-title: J Cancer – volume: 287 start-page: 7780 year: 2012 end-page: 7791 article-title: New molecular bridge between RelA/p65 and NF‐kappaB target genes via histone acetyltransferase TIP60 cofactor publication-title: J Biol Chem – volume: 448 start-page: 1063 year: 2007 end-page: 1067 article-title: Tip60 is a haplo‐insufficient tumour suppressor required for an oncogene‐induced DNA damage response publication-title: Nature – volume: 42 start-page: 584 year: 2011 end-page: 596 article-title: Phosphorylation of Tip60 by GSK‐3 determines the induction of PUMA and apoptosis by p53 publication-title: Mol Cell – volume: 276 start-page: 33066 year: 2001 end-page: 33078 article-title: Evolution of transglutaminase genes: identification of a transglutaminase gene cluster on human chromosome 15q15. Structure of the gene encoding transglutaminase X and a novel gene family member, transglutaminase Z publication-title: J Biol Chem – volume: 13 start-page: 2862 year: 2018 end-page: 2867 article-title: Modulating PCAF/GCN5 immune cell function through a PROTAC approach publication-title: ACS Chem Biol – volume: 4 start-page: 5372 year: 2014 article-title: Rational design and validation of a Tip60 histone acetyltransferase inhibitor publication-title: Sci Rep – volume: 164 start-page: 359 year: 2017 end-page: 369 article-title: Prospective open uncontrolled phase I study to define a well‐tolerated dose of oral artesunate as add‐on therapy in patients with metastatic breast cancer (ARTIC M33/2) publication-title: Breast Cancer Res Treat – volume: 71 start-page: 1356 year: 2011 end-page: 1361 article-title: Genome‐wide significant association between a sequence variant at 15q15.2 and lung cancer risk publication-title: Cancer Res – ident: e_1_2_11_8_1 doi: 10.1016/j.yexcr.2017.11.028 – ident: e_1_2_11_38_1 doi: 10.1074/jbc.M102553200 – ident: e_1_2_11_19_1 doi: 10.1158/0008-5472.CAN-17-0388 – volume: 171 issue: 1437 year: 2017 ident: e_1_2_11_21_1 article-title: A next generation connectivity map: L1000 platform and the first 1,000,000 profiles publication-title: Cell contributor: fullname: Subramanian A – ident: e_1_2_11_50_1 doi: 10.1016/j.ccell.2019.10.002 – volume: 5 start-page: 2756 year: 2015 ident: e_1_2_11_36_1 article-title: Transglutaminase 2 in cancer publication-title: Am J Cancer Res contributor: fullname: Huang L – ident: e_1_2_11_9_1 doi: 10.1038/nature03452 – ident: e_1_2_11_40_1 doi: 10.1074/jbc.M111.278465 – ident: e_1_2_11_27_1 doi: 10.1038/s41576-018-0072-4 – ident: e_1_2_11_6_1 doi: 10.1016/j.molcel.2006.11.021 – ident: e_1_2_11_13_1 doi: 10.1016/S0092-8674(00)00051-9 – ident: e_1_2_11_18_1 doi: 10.1038/s41388-021-01847-w – ident: e_1_2_11_5_1 doi: 10.1016/j.tcb.2006.07.007 – ident: e_1_2_11_15_1 doi: 10.1371/journal.pone.0164855 – ident: e_1_2_11_31_1 doi: 10.1002/dvdy.22110 – ident: e_1_2_11_22_1 doi: 10.1038/nrmicro2239 – ident: e_1_2_11_47_1 doi: 10.1007/s00280-018-3533-8 – volume: 17 start-page: 3195 year: 2019 ident: e_1_2_11_28_1 article-title: Tip60‐siRNA regulates ABCE1 acetylation to suppress lung cancer growth via activation of the apoptotic signaling pathway publication-title: Exp Ther Med contributor: fullname: Liang Z – ident: e_1_2_11_41_1 doi: 10.1038/s41388-021-02058-z – ident: e_1_2_11_44_1 doi: 10.1002/jcp.27875 – ident: e_1_2_11_24_1 doi: 10.1242/dmm.049786 – ident: e_1_2_11_20_1 doi: 10.1186/s12885-021-08158-z – ident: e_1_2_11_29_1 doi: 10.7150/jca.19677 – ident: e_1_2_11_2_1 doi: 10.3322/caac.21654 – ident: e_1_2_11_4_1 doi: 10.1016/j.biocel.2006.03.003 – ident: e_1_2_11_10_1 doi: 10.1038/nature06055 – ident: e_1_2_11_45_1 doi: 10.1111/1759-7714.13570 – ident: e_1_2_11_12_1 doi: 10.1038/cdd.2015.173 – ident: e_1_2_11_7_1 doi: 10.1016/j.molcel.2011.03.033 – ident: e_1_2_11_34_1 doi: 10.1038/nrm1014 – ident: e_1_2_11_14_1 doi: 10.1038/emboj.2010.333 – ident: e_1_2_11_43_1 doi: 10.1016/j.semcancer.2017.02.009 – ident: e_1_2_11_3_1 doi: 10.1093/bfgp/ell028 – ident: e_1_2_11_17_1 doi: 10.1016/j.ccr.2007.06.005 – ident: e_1_2_11_16_1 doi: 10.1182/blood.2019001279 – ident: e_1_2_11_32_1 doi: 10.1038/ng1361 – ident: e_1_2_11_46_1 doi: 10.1007/s10549-017-4261-1 – ident: e_1_2_11_11_1 doi: 10.1038/onc.2008.499 – ident: e_1_2_11_25_1 doi: 10.1074/jbc.M113.458737 – ident: e_1_2_11_49_1 doi: 10.1021/acschembio.8b00705 – ident: e_1_2_11_39_1 doi: 10.1158/0008-5472.CAN-10-2852 – ident: e_1_2_11_35_1 doi: 10.1111/exd.13449 – ident: e_1_2_11_42_1 doi: 10.1038/onc.2012.442 – ident: e_1_2_11_37_1 doi: 10.1007/s00726-004-0093-5 – ident: e_1_2_11_33_1 doi: 10.1074/jbc.M010157200 – ident: e_1_2_11_48_1 doi: 10.1038/s41573-021-00371-6 – ident: e_1_2_11_30_1 doi: 10.1042/BST20160081 – ident: e_1_2_11_23_1 doi: 10.1038/srep05372 – ident: e_1_2_11_26_1 doi: 10.1158/0008-5472.CAN-20-2379 |
SSID | ssj0036494 |
Score | 2.4700816 |
Snippet | Histone modifications play crucial roles in transcriptional activation, and aberrant epigenetic changes are associated with oncogenesis. Lysine (K)... Abstract Histone modifications play crucial roles in transcriptional activation, and aberrant epigenetic changes are associated with oncogenesis. Lysine (K)... |
SourceID | pubmedcentral proquest crossref pubmed wiley |
SourceType | Open Access Repository Aggregation Database Index Database Publisher |
StartPage | 2400 |
SubjectTerms | Acetyltransferase Animals Antitumor activity artemisinin Cancer therapies Carcinogenesis - genetics Carcinoma, Non-Small-Cell Lung - genetics Cell adhesion & migration Cell culture Cell growth Cell migration Cell Transformation, Neoplastic - genetics Cloning Comparative analysis Datasets Epigenetics Experiments Histone Acetyltransferases - genetics Histone Acetyltransferases - metabolism Histones Homeostasis Humans Hypotheses KAT5 Kinases Lung cancer Lung Neoplasms - genetics Mice Mutation Non-small cell lung carcinoma Original Prostate Proteins Sarcoma Small cell lung carcinoma TGM5 TIP60 Transcription activation Tumor cell lines Tumorigenesis Wound healing |
SummonAdditionalLinks | – databaseName: ProQuest Databases dbid: BENPR link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1LS8QwEB58gHgR39YXUTx4KTZN2qYnWUVRQREf4K0kaYoL66r7-P_OtOnqInorJDTNTDL5vsl0BuAo55Zz40QoVJkgQXEq1DbPwkynpbVxlZeG_JC3d-nVs7x5SV68w23owypbm1gb6vLdko_8BKkBR2wsM3H68RlS1Si6XfUlNGZhPuaSrmnnzy7u7h9aWyxSmTdlbWUW5pGIfW4hiuWhkmKcUr1Mn0i_YObvaMmfKLY-hi6XYcnjR9ZpFL4CM66_Cgu3_oZ8DTpP1_dpxLpDNnAU5OtKhrCUjcZvNBkybNjU7TNk_eHwTfd6jFz3rId7nllaAYN1eL68eDq_Cn2ZhNDKlH4dcKU2SVbhuVJVRJjQvkkljeBSGxNl1iIq0IispDEJwguXCK2liZGdpmViI7EBczio2wJWp8vjNlK6qmQcWa2kq_AdyDpUhUwvgMNWVMVHkw2jaFkEyrOo5RnAbivEwm-IYfGtvgAOJs24lGmSuu_ex9gnU5QNjfMsgM1G5pNRRIo4Nk9UAGpKG5MOlCZ7uqXffa3TZVNyCsRVeQDHteL-_vLivPNYP2z_P4UdWKSq803E2C7MjQZjt4fYZGT2_QL8Asyq4ZU priority: 102 providerName: ProQuest – databaseName: Wiley Online Library - Core collection (SURFmarket) dbid: DR2 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LS8QwEB7Eg3jx_agvonjwUmk3aZviSRYXFVbEB3gQSpKmuLhW2cfFkz_B3-gvcaYvXEUQb4WkTZPJTL5JJt8A7Me-8X1tuctlGqCDYqWrTBy5kQpTY1pZnGrah-xehKe34vwuuJuCo_ouTMkP0Wy4kWYU9poUXOnhFyWnlGA-UbWg_SUiPQJEVw11FA9FXCa0FZEbe7xVsQpRFE_z5uRa9ANg_oyT_IpfiwWoMw_39a-XcSePh-ORPjSv31gd_9m3BZirgCk7LmfSIkzZfAlmutXR-zK0b84uQ4_1hmxgKXrYpgzxLhuNnyi3FllMLOrlLH_OP97eh0-q32d0KsD6aE6Yock1WIHbzslN-9StMjC4RoR0K8GmSgdRhktWlpEvhqZTSKG5L5TWXmQMAg6FoE1oHSBysQFXSugWOr5hGhiPr8I0NmvXgRVMfL7xpMoy0fKMksJm-A10aGSGTqQDe7UskpeSaCOpHRQcjqQYDge2aiklla4NE3QasTAUEXdgtylGLaFOqtw-j7FOJIlozfcjB9ZKoTat8BAhchxIB-SEuJsKxMA9WZL3HgombuK9QMgWO3BQiPP3P0_ax9fFw8bfq27CLCW3LwPTtmB6NBjbbYRAI71TzPVP7ZgCGA priority: 102 providerName: Wiley-Blackwell |
Title | TIP60 is required for tumorigenesis in non‐small cell lung cancer |
URI | https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fcas.15785 https://www.ncbi.nlm.nih.gov/pubmed/36916958 https://www.proquest.com/docview/2821576473 https://www.proquest.com/docview/2786812117/abstract/ https://pubmed.ncbi.nlm.nih.gov/PMC10236639 |
Volume | 114 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NTtwwEB6xICEuVaG0TUtXbsWBS9gkduzkSFcgqLRoxY_ELbIdR6y0m6L9ufcR-ow8CTNOsgIhLlyiSGPFyXjs-T5nPANwmMc2jo3jIc_KFAmKy0JtcxUqLUtrkyovDe1Dji7l-a34c5febYDszsL4oH1rJsf1dHZcT-59bOXDzA66OLHBeDSkdAPoKfNBD3qK846jN-svlyJvStkKFeYRT9p8QhS_Q2XEYkrvsgPbXCIyyqnU-3OH9Aplvg6WfA5ivRc6-wgfWvjITprX3IUNV-_B9qj9Qf4JhjcXYxmxyYLNHcX4upIhKmXL1YwqYNG6hqJJzZD0P_77v5jp6ZTR3j2b4qRnlkxgvg-3Z6c3w_OwrZMQWiHp7IArtUlVhY6lqogx4QInMmF4LLQxkbIWYYFGaCWMSRFfuJRrLUyC9FSWqY34Z9jEbt1XYD5fXmyjTFeVSCKrM-EqfAbSjqxCqhfAr05ZxUOTDqPoaAQqt_DKDeCgU2PRzohFgdQOhVIoHsDPtRhtmT5S1-7vCtuojNKhxbEK4Euj9XUv3XAFkL0Yj3UDypP9UoLm4_Nld-YSwJEfurffvBieXPubb-_v5TvsUEn6JpzsADaX85X7gcBlafrQS8S4D1u_Ty_HV31P_-l6lfS9BT8Bi2_vpw |
link.rule.ids | 230,315,733,786,790,870,891,1382,11589,21416,27955,27956,33777,33778,43838,46085,46327,46509,46751,50847,50956,53825,53827,74657 |
linkProvider | National Library of Medicine |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3dT9swED9BkcZeEGwMwvjwJh54iRbXTuI8oYJAZaMVgiLxFtmOIyqVwvrx_-8ucToqBG-RbMXxnX3-3fnyO4DjjFvOjROhUEWMDopTobZZGqY6Kaxtl1lhKA7Z6yfde_n7IX7wAbepT6tsbGJlqItnSzHyX-gacMTGMhWnL39DqhpFt6u-hMYqrBHlpmrB2tlF_-a2scUikVld1lamYRaJtucWolweKinGiepl-UR6AzPfZku-RrHVMXS5CRseP7JOrfAtWHHjL_Cp52_Iv0JncHWTRGw4ZRNHSb6uYAhL2Wz-RJMhw4ZNwzFDrz-cPunRiFHono1wzzNLK2CyDfeXF4PzbujLJIRWJvTrgCu0idMSz5WyJIcJ7ZtU0ggutTFRai2iAo3IShoTI7xwsdBamjZ6p0kR20h8gxYO6naBVXR53EZKl6VsR1Yr6Up8B3odqkRPL4Cfjajyl5oNI2-8CJRnXskzgP1GiLnfENP8v_oC-LFoxqVMk9Rj9zzHPqkiNjTO0wB2apkvRhEJ4tgsVgGoJW0sOhBN9nLLePhY0WUTOQXiqiyAk0px7395ft65qx72Pp7CEax3B73r_Pqq_-c7fKYK9HX22D60ZpO5O0CcMjOHfjH-A57N5Is |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwEB5BK1VcEFAegQIu4tBL1HjtxM4JLaWrFuhqRVupt8h2bLHSNlv28f-ZSZyFVQW3SLbieGY8_j57MgPwseSOc-tFKnSdI0HxOjWuVKkyRe3cIJS1pXPIi3Fxdi2_3uQ3Mf5pGcMqe5_YOup67uiM_BipAUdsLJU4DjEsYvJl9OnuV0oVpOimNZbTeAi7ShY5ErHdz6fjyY_eL4tCll2JW6nSMhODmGeI4nqovBintC_bu9M9yHk_cvJvRNtuSaMn8DhiSTbslP8UHvjmGexdxNvyfRhenU-KjE2XbOEp4NfXDCEqW61vaTLk5LBp2rBm3qTLWzObMTrGZzNc_8yRNSyew_Xo9OrkLI0lE1InC_qNwNfG5irgHhMCkSf0dVJLK7g01mbKOUQIBlGWtDZHqOFzYYy0A2SqRZ27TLyAHRzUvwLWps7jLtMmBDnInNHSB3wHMhAdkPUl8KEXVXXXZcaoekaB8qxaeSZw0AuxiotjWf1RZQKHm2Y0a5qkafx8jX2UpsxonKsEXnYy34wiCsS0Za4T0Fva2HSglNnbLc30Z5s6mxJVIMYqEzhqFffvL69Ohpftw-v_T-E97KEdVt_Px9_ewCMqRt8Fkh3Azmqx9m8Rsqzsu2iLvwFhMOi_ |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=TIP60+is+required+for+tumorigenesis+in+non%E2%80%90small+cell+lung+cancer&rft.jtitle=Cancer+science&rft.au=Shibahara%2C+Daisuke&rft.au=Akanuma%2C+Naoki&rft.au=Kobayashi%2C+Ikei+S.&rft.au=Heo%2C+Eunyoung&rft.date=2023-06-01&rft.pub=John+Wiley+and+Sons+Inc&rft.issn=1347-9032&rft.eissn=1349-7006&rft.volume=114&rft.issue=6&rft.spage=2400&rft.epage=2413&rft_id=info:doi/10.1111%2Fcas.15785&rft_id=info%3Apmid%2F36916958&rft.externalDBID=PMC10236639 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1347-9032&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1347-9032&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1347-9032&client=summon |